

Information Sorted by Substance Name and Assay

Assay Type*	Reference Androgen**	Substance Name	CASRN†	AGONISM ^b Qualitative††	AGONISM Maximum Fold x (conc. μM)††	AGONISM EC50 (μM)††	ANTAG. ^{a,b} Qualitative††	ANTAG. ^{a,b} IC50 (μM)††	Prolif. Response ^a ††	RPP ^{a,b,†} ††	Reference
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Aldosterone	52-39-1	neg.							Otsuka Pharmaceutical Co. (2001)
EPC rtAR () +CAT(T)	DHT	Aldosterone	52-39-1	neg.							Takeo and Yamashita (2000)
PALM hAR(S)+Luc(S)	R1881	Aldosterone	52-39-1	neg.	2x (1μM)						Terouanne et al. (2000)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	<i>t</i> -Allethrin	584-79-2	neg.							Gaido et al. (1997)
CHO hAR(T)+CAT(T)+ gal(T)	DHT	Allopregnanedione	566-65-4	neg.	1x (2nM)						Deslypere et al. (1992)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Anastrozole	120511-73-1	neg.			neg.				O'Connor et al. (1998)
LNcaP-FGC hAR(E)+CP	DHT	5 -Androstane-3 ,17 -diol	1852-53-5						weak	0.1	Sonnenschein et al. (1989)
LNcaP-FGC hAR(E)+CP	DHT	5 -Androstane-3 ,17 -diol	126061-67-4						pos.	10	Sonnenschein et al. (1989)
CHO hAR(T)+CAT(T)+ gal(T)	DHT	Androstenedione	63-05-8	pos.	65x (1nM)						Deslypere et al. (1992)
CHO-K1 hAR(S)+Luc(S)	DHT	Androstenedione	63-05-8	pos.		0.00242					Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Androstenedione	63-05-8	pos.		0.000645					Otsuka Pharmaceutical Co. (2001)
CHO hAR(T)+Luc(T)	R1881	Anthracene	120-12-7				neg.				Vinggaard et al. (2000)
Yeast(<i>S. cer</i>) hAR(S)+ gal(S)	DHT	Ascorbic acid	50-81-7	neg.			neg.				Moffat et al. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Atrazine	1912-24-9	neg.							Otsuka Pharmaceutical Co. (2001)
PALM hAR(S)+Luc(S)	R1881	Atrazine	1912-24-9				neg.				Sultan et al. (2001)
CHO hAR(T)+Luc(T)	R1881	Benz[<i>a</i>]anthracene	56-55-3				pos.	3.2			Vinggaard et al. (2000)
CHO hAR(T)+Luc(T)	R1881	Benzo[<i>a</i>]pyrene	50-32-8				pos.	3.9			Vinggaard et al. (2000)
CV-1 hAR(T)+Luc(T)	DHT	Bicalutamide	90357-06-5	weak			pos.				Kempainen and Wilson (1996)
PALM hAR(S)+Luc(S)	R1881	Bicalutamide	90357-06-5				pos.	0.75			Terouanne et al. (2000)
PALM hAR(S)+Luc(S)	R1881	Bicalutamide	90357-06-5	weak	5x (1μM)		pos.	18			Terouanne et al. (2000)
PC-3 hAR(T)+Luc(T)	R1881	Bicalutamide	90357-06-5				pos.	0.5			Terouanne et al. (2000)
CHO hAR(T)+Luc(T)	R1881	Bicalutamide	90357-06-5				pos.	0.5			Vinggaard et al. (1999)

Information Sorted by Substance Name and Assay

Assay Type*	Reference Androgen**	Substance Name	CASRN†	AGONISM Qualitative††	AGONISM Maximum Fold x (conc. µM)††	AGONISM EC50 (µM)††	ANTAG. ^{a,b} Qualitative††	ANTAG. ^{a,b} IC50 (µM)††	Prolif. Response ^a ††	RPP ^{a,b,††}	Reference
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	2,2-Bis(<i>p</i> -hydroxyphenyl)-1,1,1-trichloroethane	2971-36-0	neg.							Otsuka Pharmaceutical Co. (2001)
CV-1 hAR(T)+Luc(T)*	DHT	2,2-Bis(<i>p</i> -hydroxyphenyl)-1,1,1-trichloroethane	2971-36-0	pos.			pos.				Hartig et al. (2002)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	2,2-Bis(<i>p</i> -hydroxyphenyl)-1,1,1-trichloroethane	2971-36-0				pos.				Gaido et al. (2000)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	2,2-Bis(<i>p</i> -hydroxyphenyl)-1,1,1-trichloroethane	2971-36-0				pos.				Maness et al. (1998)
MDA-MB-453 hAR(E)+Luc(T)*	DHT	2,2-Bis(<i>p</i> -hydroxyphenyl)-1,1,1-trichloroethane	2971-36-0	pos.			pos.	0.1			Hartig et al. (2002)
MDA-MB-453-kb2 hAR(E)+Luc(S)	DHT	2,2-Bis(<i>p</i> -hydroxyphenyl)-1,1,1-trichloroethane	2971-36-0				pos.	10			Wilson et al. (2002)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Bisphenol A	80-05-7	neg.							Otsuka Pharmaceutical Co. (2001)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	Bisphenol A	80-05-7				neg.				Gaido et al. (2000)
PALM hAR(S)+Luc(S)	R1881	Bisphenol A	80-05-7				pos.	1			Sultan et al. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Bisphenol B	77-40-7	neg.							Otsuka Pharmaceutical Co. (2001)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	Bisphenol E	6052-84-2				pos.				Gaido et al. (2000)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	4,4'-Bisphenol F	620-92-8				pos.				Gaido et al. (2000)
PALM hAR(S)+Luc(S)	DHT	Butylated hydroxyanisole	25013-16-5	neg.			pos.	7.6			Schrader and Cooke (2000)
PALM hAR(S)+Luc(S)	DHT	Butylated hydroxytoluene	128-37-0	neg.			pos.	5.7			Schrader and Cooke (2000)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Butyl benzyl phthalate	85-68-7	neg.							Otsuka Pharmaceutical Co. (2001)
PALM hAR(S)+Luc(S)	R1881	Butyl benzyl phthalate	85-68-7				neg.				Sultan et al. (2001)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Butyl benzyl phthalate	85-68-7	neg.							Gaido et al. (1997)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Chlornitrofen	1836-77-7	pos.			weak				Otsuka Pharmaceutical Co. (2001)
LNCAp-FGC hAR(E)+CP	DHT	11 -Chloromethyl estradiol	71794-60-0						pos.	1	Sonnenschein et al. (1989)
CHO hAR(T)+Luc(T)	R1881	Chrysene	218-01-9				pos.	10.3			Vinggaard et al. (2000)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Clomiphene	911-45-5	neg.							Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Corticosterone	50-22-6	neg.							Otsuka Pharmaceutical Co. (2001)

Information Sorted by Substance Name and Assay

Assay Type*	Reference Androgen**	Substance Name	CASRN†	AGONISM ^b Qualitative††	AGONISM Maximum Fold x (conc. μM)††	AGONISM EC50 (μM)††	ANTAG. ^{a,b} Qualitative††	ANTAG. ^{a,b} IC50 (μM)††	Prolif. Response ^a ††	RPP ^{a,b,††}	Reference
CHO hAR(T)+CAT(T)+ gal(T)	DHT	Cortisol	50-23-7	pos.	35x (1μM)						Deslypere et al. (1992)
CHO-K1 hAR(S)+Luc(S)	DHT	Cortisol	50-23-7	pos.		0.0427					Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Cortisol	50-23-7	neg.							Otsuka Pharmaceutical Co. (2001)
PALM hAR(S)+Luc(S)	DHT	Cortisol	50-23-7	pos.							Schrader and Cooke (2000)
PALM hAR(S)+Luc(S)	R1881	Cortisol	50-23-7	pos.	20x (1μM)						Terouanne et al. (2000)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Cortisol	50-23-7	neg.							Gaido et al. (1997)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Coumestrol	479-13-0	neg.							Otsuka Pharmaceutical Co. (2001)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Coumestrol	479-13-0	neg.							Gaido et al. (1997)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Coumestrol	479-13-0	neg.							O'Connor et al. (2000)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	<i>p</i> -Cumylphenol	599-64-4	neg.							Otsuka Pharmaceutical Co. (2001)
CHO hAR(T)+Luc(T)	R1881	Cyproterone acetate	427-51-0				pos.	0.5			Vinggaard et al. (1999)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Cyproterone acetate	427-51-0	pos.							Otsuka Pharmaceutical Co. (2001)
CV-1 hAR(T)+CAT(T)	R1881	Cyproterone acetate	427-51-0	pos.	15x (10nM)		pos.				Kemppainen et al. (1992)
CV-1 hAR(T)+Luc(T)	DHT	Cyproterone acetate	427-51-0	pos.	10x (0.1μM)		pos.	0.1			Kemppainen et al. (1999)
HeLa hAR(S)+DS-Luc(T)	DHT	Cyproterone acetate	427-51-0	weak	2x (100nM)						Wang and Fondell (2001)
HeLa hAR(S)+M-Luc(T)	DHT	Cyproterone acetate	427-51-0	weak	0.5x (100nM)						Wang and Fondell (2001)
PALM hAR(S)+Luc(S)	R1881	Cyproterone acetate	427-51-0	pos.			pos.	0.01			Terouanne et al. (2000)
PALM hAR(S)+Luc(S)	R1881	Cyproterone acetate	427-51-0	pos.	30x (1μM)		pos.	45			Terouanne et al. (2000)
PC-3 hAR(T)+Luc(T)	R1881	Cyproterone acetate	427-51-0	pos.			pos.	0.01			Terouanne et al. (2000)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	<i>o,p'</i> -DDD	53-19-0				pos.				Maness et al. (1998)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	<i>p,p'</i> -DDD	72-54-8	neg.							Otsuka Pharmaceutical Co. (2001)
CV-1 hAR(T)+Luc(T)	DHT	<i>p,p'</i> -DDD	72-54-8				pos.				Kelce et al. (1995)

Information Sorted by Substance Name and Assay

Assay Type*	Reference Androgen**	Substance Name	CASRN†	AGONISM Qualitative††	AGONISM Maximum Fold x (conc. μ M)††	AGONISM EC50 (μ M)††	ANTAG. ^{a,b} Qualitative††	ANTAG. ^{a,b} IC50 (μ M)††	Prolif. Response ^a ††	RPP ^{a,b,†} ††	Reference
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	<i>p,p'</i> -DDD	72-54-8				pos.				Maness et al. (1998)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	<i>p,p'</i> -DDD	72-54-8	neg.							Gaido et al. (1997)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	<i>o,p'</i> -DDE	3424-82-6	neg.							Otsuka Pharmaceutical Co. (2001)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	<i>o,p'</i> -DDE	3424-82-6				pos.				Maness et al. (1998)
PALM hAR(S)+Luc(S)	R1881	<i>o,p'</i> -DDE	3424-82-6				pos.	1.5			Sultan et al. (2001)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	<i>o,p'</i> -DDE	3424-82-6	neg.							Gaido et al. (1997)
CHO hAR(T)+Luc(T)	R1881	<i>p,p'</i> -DDE	72-55-9				pos.	1			Vinggaard et al. (1999)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	<i>p,p'</i> -DDE	72-55-9	neg.							Otsuka Pharmaceutical Co. (2001)
CV-1 hAR(T)+Luc(T)	DHT	<i>p,p'</i> -DDE	72-55-9				pos.				Kelce et al. (1995)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	<i>p,p'</i> -DDE	72-55-9				pos.				Gaido et al. (2000)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	<i>p,p'</i> -DDE	72-55-9	weak			pos.				Maness et al. (1998)
MDA-MB-453-kb2 hAR(E)+Luc(S)	DHT	<i>p,p'</i> -DDE	72-55-9				pos.	5			Wilson et al. (2002)
PALM hAR(S)+Luc(S)	DHT	<i>p,p'</i> -DDE	72-55-9	pos.			pos.	15.2			Schrader and Cooke (2000)
PALM hAR(S)+Luc(S)	R1881	<i>p,p'</i> -DDE	72-55-9				pos.	0.75			Sultan et al. (2001)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	<i>p,p'</i> -DDE	72-55-9	weak		8820					Gaido et al. (1997)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	<i>p,p'</i> -DDE	72-55-9	neg.							Gaido et al. (1997)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	<i>p,p'</i> -DDE	72-55-9	pos.		350	neg.				O'Connor et al. (1999)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	<i>o,p'</i> -DDT	789-02-6	neg.							Otsuka Pharmaceutical Co. (2001)
CV-1 hAR(T)+Luc(T)	DHT	<i>o,p'</i> -DDT	789-02-6				pos.				Kelce et al. (1995)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	<i>o,p'</i> -DDT	789-02-6				pos.				Maness et al. (1998)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	<i>o,p'</i> -DDT	789-02-6	neg.							Gaido et al. (1997)
CV-1 hAR(T)+Luc(T)	DHT	<i>p,p'</i> -DDT	50-29-3				pos.				Kelce et al. (1995)

Information Sorted by Substance Name and Assay

Assay Type*	Reference Androgen**	Substance Name	CASRN†	AGONISM Qualitative††	AGONISM Maximum Fold x (conc. µM)††	AGONISM EC50 (µM)††	ANTAG. ^{a,b} Qualitative††	ANTAG. ^{a,b} IC50 (µM)††	Prolif. Response ^a ††	RPP ^{a,b,††}	Reference
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	<i>p,p'</i> -DDT	50-29-3				pos.				Maness et al. (1998)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	<i>p,p'</i> -DDT	50-29-3	neg.							Gaido et al. (1997)
CHO hAR (S)+Luc (S)	DHT	15-Dehydroetionogestrel		neg.							Deckers et al. (2000)
CHO hAR (S)+Luc (S)	DHT	15-Dehydronorethisterone		neg.							Deckers et al. (2000)
CHO hAR(T)+Luc(T)	R1881	Dexamethasone	50-02-2	neg. ^b							Vinggaard et al. (1999)
CV-1 hAR(T)+Luc(T)*	DHT	Dexamethasone	50-02-2		3x (0.1µM)						Hartig et al. (2002)
EPC rtAR () +CAT(T)	DHT	Dexamethasone	50-02-2	neg.							Takeo and Yamashita (2000)
MDA-MB-453 hAR(E)+Luc(T)*	DHT	Dexamethasone	50-02-2	pos. ^b	248x (1µM)						Hartig et al. (2002)
PALM hAR(S)+Luc(S)	DHT	Dexamethasone	50-02-2	pos.							Schrader and Cooke (2000)
PALM hAR(S)+Luc(S)	R1881	Dexamethasone	50-02-2	pos.	30x (1µM)						Terouanne et al. (2000)
CHO hAR(T)+Luc(T)	R1881	Dibenzo[<i>a,h</i>]anthracene	53-70-3	pos.							Vinggaard et al. (2000)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Dibutyl phthalate	84-74-2	neg.							Otsuka Pharmaceutical Co. (2001)
CV-1 hAR(T)+Luc(T)*	DHT	3',5'-Dichloro-2-hydroxy-2-methylbut-3-enanilide	16776-82-1	pos.	17x (10µM)		pos.				Hartig et al. (2002)
MDA-MB-453 hAR(E)+Luc(T)*	DHT	3',5'-Dichloro-2-hydroxy-2-methylbut-3-enanilide	16776-82-1	pos.			pos.	0.1			Hartig et al. (2002)
MDA-MB-453-kb2 hAR(E)+Luc(S)	DHT	3',5'-Dichloro-2-hydroxy-2-methylbut-3-enanilide	16776-82-1				pos.	0.2			Wilson et al. (2002)
PALM hAR(S)+Luc(S)	R1881	3',5'-Dichloro-2-hydroxy-2-methylbut-3-enanilide	16776-82-1				pos.	0.02			Sultan et al. (2001)
CV-1 hAR(T)+Luc(T)*	DHT	(4-[2,2-Dichloro-1-(4-hydroxyphenyl)vinyl]phenol)		pos.	8.4x (10µM)						Hartig et al. (2002)
MDA-MB-453 hAR(E)+Luc(T)*	DHT	(4-[2,2-Dichloro-1-(4-hydroxyphenyl)vinyl]phenol)		pos.				0.1			Hartig et al. (2002)
MDA-MB-453-kb2 hAR(E)+Luc(S)	DHT	(4-[2,2-Dichloro-1-(4-hydroxyphenyl)vinyl]phenol)					pos.	5			Wilson et al. (2002)
CV-1 hAR(T)+Luc(T)*	DHT	2-[[3,5-Dichlorophenyl]carbamoyl]oxy]-2-methyl-3-butenic acid	119209-27-7	pos.	9.1x (10µM)		pos.				Hartig et al. (2002)
MDA-MB-453 hAR(E)+Luc(T)*	DHT	2-[[3,5-Dichlorophenyl]carbamoyl]oxy]-2-methyl-3-butenic acid	119209-27-7	pos.			pos.	0.1			Hartig et al. (2002)

Information Sorted by Substance Name and Assay

Assay Type*	Reference Androgen**	Substance Name	CASRN†	AGONISM Qualitative††	AGONISM Maximum Fold x (conc. µM)††	AGONISM EC50 (µM)††	ANTAG. ^{a,b} Qualitative††	ANTAG. ^{a,b} IC50 (µM)††	Prolif. Response ^a ††	RPP ^{a,b,††}	Reference
MDA-MB-453-kb2 hAR(E)+Luc(S)	DHT	2-[[3,5-Dichlorophenyl]carbamoyl]oxy]-2-methyl-3-butenic acid	119209-27-7				pos.	0.2			Wilson et al. (2002)
PALM hAR(S)+Luc(S)	R1881	2-[[3,5-Dichlorophenyl]carbamoyl]oxy]-2-methyl-3-butenic acid	119209-27-7				pos.	0.5			Sultan et al. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Dicofol	115-32-2	neg.							Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Di-(2-ethylhexyl)phthalate	117-81-7	neg.							Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Diethylstilbestrol	56-53-1	neg.							Otsuka Pharmaceutical Co. (2001)
CV-1 hAR(T)+Luc(T)	DHT	Diethylstilbestrol	56-53-1				pos.				Kelce et al. (1995)
LNCaP-FGC hAR(E)+CP	DHT	Diethylstilbestrol	56-53-1						neg.		Sonnenschein et al. (1989)
PALM hAR(S)+Luc(S)	DHT	Diethylstilbestrol	56-53-1	neg.			pos.	0.36			Schrader and Cooke (2000)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Diethylstilbestrol	56-53-1	neg.							Gaido et al. (1997)
CHO hAR (S)+Luc (S)	DHT	5 -Dihydrotestosterone	521-18-6	pos.							Deckers et al. (2000)
CHO hAR(T)+CAT(T)+ gal(T)	DHT	5 -Dihydrotestosterone	521-18-6	pos.	100x (0.1nM)						Deslypere et al. (1992)
CHO-K1 hAR(S)+Luc(S)	DHT	5 -Dihydrotestosterone	521-18-6	pos.		0.000153					Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	5 -Dihydrotestosterone	521-18-6	pos.		0.000153					Otsuka Pharmaceutical Co. (2001)
CV-1 hAR(T)+CAT(T)	R1881	5 -Dihydrotestosterone	521-18-6	pos.	7.0x (0.01nM)						Kemppainen et al. (1992)
CV-1 hAR(T)+Luc(T)	DHT	5 -Dihydrotestosterone	521-18-6	pos.							Kelce et al. (1995)
CV-1 hAR(T)+Luc(T)	DHT	5 -Dihydrotestosterone	521-18-6	pos.							Kemppainen and Wilson (1996)
CV-1 hAR(T)+Luc(T)	DHT	5 -Dihydrotestosterone	521-18-6	pos.	10x (0.001nM)						Kemppainen et al. (1999)
CV-1 hAR(T)+Luc(T)	DHT	5 -Dihydrotestosterone	521-18-6	pos.							Lambright et al. (2000)
CV-1 hAR(T)+Luc(T)*	DHT	5 -Dihydrotestosterone	521-18-6	pos.	45x (0.1nM)						Hartig et al. (2002)
CV-1 mAR(T)+CAT(T)	DHT	5 -Dihydrotestosterone	521-18-6	pos.							Van Dort et al. (2000)
EPC rtAR () +CAT(T)	DHT	5 -Dihydrotestosterone	521-18-6	pos.							Takeo and Yamashita (2000)

Information Sorted by Substance Name and Assay

Assay Type*	Reference Androgen**	Substance Name	CASRN†	AGONISM Qualitative††	AGONISM Maximum Fold x (conc. μ M)††	AGONISM EC50 (μ M)††	ANTAG. ^{a,b} Qualitative††	ANTAG. ^{a,b} IC50 (μ M)††	Prolif. Response ^a ††	RPP ^{a,b,†} ††	Reference
HeLa hAR(S)+DS-Luc(T)	DHT	5 -Dihydrotestosterone	521-18-6	pos.	7x (100nM)						Wang and Fondell (2001)
HeLa hAR(S)+M-Luc(T)	DHT	5 -Dihydrotestosterone	521-18-6	pos.	4.5x (100nM)						Wang and Fondell (2001)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	5 -Dihydrotestosterone	521-18-6	pos.							Gaido et al. (2000)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	5 -Dihydrotestosterone	521-18-6	pos.							Maness et al. (1998)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	5 -Dihydrotestosterone	521-18-6	pos.							Tamura et al. (2001)
LNCaP-FGC hAR(E)+CP	DHT	5 -Dihydrotestosterone	521-18-6						pos.	100	Sonnenschein et al. (1989)
MDA-MB-453 hAR(E)+Luc(T)*	DHT	5 -Dihydrotestosterone	521-18-6	pos.	23.7x (0.1nM)						Hartig et al. (2002)
MDA-MB-453-kb2 hAR(E)+Luc(S)	DHT	5 -Dihydrotestosterone	521-18-6								Lambright et al. (2000)
MDA-MB-453-kb2 hAR(E)+Luc(S)	DHT	5 -Dihydrotestosterone	521-18-6	pos.							Wilson et al. (2002)
PALM hAR(S)+Luc(S)	DHT	5 -Dihydrotestosterone	521-18-6	pos.							Schrader and Cooke (2000)
PALM hAR(S)+Luc(S)	R1881	5 -Dihydrotestosterone	521-18-6	pos.							Sultan et al. (2001)
PALM hAR(S)+Luc(S)	R1881	5 -Dihydrotestosterone	521-18-6	pos.		0.00004					Terouanne et al. (2000)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	5 -Dihydrotestosterone	521-18-6	pos.		0.0035					Gaido et al. (1997)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	5 -Dihydrotestosterone	521-18-6	pos.							O'Connor et al. (1998)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	5 -Dihydrotestosterone	521-18-6	pos.							O'Connor et al. (1999)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	5 -Dihydrotestosterone	521-18-6	pos.		0.0024					O'Connor et al. (2000)
Yeast(<i>S. cer</i>) hAR(S)+ gal(S)	DHT	5 -Dihydrotestosterone	521-18-6	pos.		0.002		100			Moffat et al. (2001)
CHO hAR(T)+CAT(T)+ gal(T)	DHT	5 -Dihydrotestosterone	571-22-2	pos.	5x (1nM)						Deslypere et al. (1992)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	4,4'-Dihydroxybenzophenone	611-99-4				neg.				Gaido et al. (2000)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	Dihydroxy-DDE					pos.				Gaido et al. (2000)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	4,4-Dimethoxybenzhydrol	728-87-0				neg.				Gaido et al. (2000)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	Dimethoxy-DDE					pos.				Gaido et al. (2000)

Information Sorted by Substance Name and Assay

Assay Type*	Reference Androgen**	Substance Name	CASRN†	AGONISM ^b Qualitative††	AGONISM Maximum Fold x (conc. µM)††	AGONISM EC50 (µM)††	ANTAG. ^{a,b} Qualitative††	ANTAG. ^{a,b} IC50 (µM)††	Prolif. Response ^a ††	RPP ^{a,b,††}	Reference
CHO hAR(T)+Luc(T)	R1881	Dimethylbenz[<i>a</i>]anthracene	57-97-6	pos.			pos.	10.4			Vinggaard et al. (2000)
PALM hAR(S)+Luc(S)	R1881	Diphenylphthalate	84-62-8				neg.				Sultan et al. (2001)
CV-1 mAR(T)+CAT(T)	DHT	DTIB		pos.							Van Dort et al. (2000)
CHO hAR(T)+CAT(T)+ gal(T)	DHT	Epitestosterone	481-30-1	pos.	15x (1nM)						Deslypere et al. (1992)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Equilin	474-86-2	neg.							Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Equol	531-95-3	neg.							Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	17 -Estradiol	57-91-0	neg.							Otsuka Pharmaceutical Co. (2001)
CHO hAR(T)+CAT(T)+ gal(T)	DHT	17 -Estradiol	50-28-2	pos.	40x (1nM)						Deslypere et al. (1992)
CHO hAR(T)+Luc(T)	R1881	17 -Estradiol	50-28-2	pos.			pos.	1			Vinggaard et al. (1999)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	17 -Estradiol	50-28-2	weak							Otsuka Pharmaceutical Co. (2001)
CV-1 hAR(T)+CAT(T)	R1881	17 -Estradiol	50-28-2	pos.	7.0x (10nM)						Kemppainen et al. (1992)
CV-1 hAR(T)+Luc(T)	DHT	17 -Estradiol	50-28-2				pos.				Kelce et al. (1995)
CV-1 hAR(T)+Luc(T)	DHT	17 -Estradiol	50-28-2	pos.							Kemppainen and Wilson (1996)
CV-1 hAR(T)+Luc(T)	DHT	17 -Estradiol	50-28-2	pos.	10x (0.01µM)		pos.	0.5			Kemppainen et al. (1999)
CV-1 hAR(T)+Luc(T)*	DHT	17 -Estradiol	50-28-2								Hartig et al. (2002)
EPC rtAR () +CAT(T)	DHT	17 -Estradiol	50-28-2	neg.							Takeo and Yamashita (2000)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	17 -Estradiol	50-28-2	pos.			pos.				Maness et al. (1998)
LNCaP-FGC hAR(E)+CP	DHT	17 -Estradiol	50-28-2						pos.	1	Sonnenschein et al. (1989)
MDA-MB-453 hAR(E)+Luc(T)*	DHT	17 -Estradiol	50-28-2	pos.							Hartig et al. (2002)
MDA-MB-453-kb2 hAR(E)+Luc(S)	DHT	17 -Estradiol	50-28-2	pos.			pos.	0.05			Wilson et al. (2002)
PALM hAR(S)+Luc(S)	DHT	17 -Estradiol	50-28-2	pos.							Schrader and Cooke (2000)
PALM hAR(S)+Luc(S)	R1881	17 -Estradiol	50-28-2	neg.	2x (1µM)						Terouanne et al. (2000)

Information Sorted by Substance Name and Assay

Assay Type*	Reference Androgen**	Substance Name	CASRN†	AGONISM Qualitative††	AGONISM Maximum Fold x (conc. μ M)††	AGONISM EC50 (μ M)††	ANTAG. ^{a,b} Qualitative††	ANTAG. ^{a,b} IC50 (μ M)††	Prolif. Response ^a ††	RPP ^{a,b,†} †	Reference
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	17 -Estradiol	50-28-2	pos.		0.0861					Gaido et al. (1997)
LNCaP-FGC hAR(E)+CP	DHT	Estriol	50-27-1						neg.		Sonnenschein et al. (1989)
CHO-K1 hAR(S)+Luc(S)	DHT	Estrone	53-16-7	pos.		0.0551					Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Estrone	53-16-7	weak							Otsuka Pharmaceutical Co. (2001)
LNCaP-FGC hAR(E)+CP	DHT	Estrone	53-16-7						neg.		Sonnenschein et al. (1989)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	17 -Ethinyl estradiol	57-63-6	neg.							Otsuka Pharmaceutical Co. (2001)
LNCaP-FGC hAR(E)+CP	DHT	17 -Ethinyl estradiol	57-63-6						pos.	1	Sonnenschein et al. (1989)
CHO hAR (S)+Luc (S)	DHT	Etonogestrel	54048-10-1	pos.							Deckers et al. (2000)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Fenbuconazole	114369-43-6	neg.							Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Fenitrothion	122-14-5	pos.			pos.				Otsuka Pharmaceutical Co. (2001)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	Fenitrothion	122-14-5	weak			pos.				Tamura et al. (2001)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Fenvalerate	51630-58-1	neg.							Gaido et al. (1997)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Finasteride	98319-26-7	neg.			neg.				O'Connor et al. (1998)
CHO hAR(T)+Luc(T)	R1881	Fluoranthene	206-44-0				pos.	4.6			Vinggaard et al. (2000)
CV-1 hAR(T)+Luc(T)	DHT	Fluoxymesterone	76-43-7	pos.	10x (0.001 μ M)		neg.				Kemppainen et al. (1999)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Flutamide	13311-84-7	neg.							Otsuka Pharmaceutical Co. (2001)
CV-1 hAR(T)+CAT(T)	R1881	Flutamide	13311-84-7	neg.			pos.				Kemppainen et al. (1992)
HeLa hAR(S)+DS-Luc(T)	DHT	Flutamide	13311-84-7	neg.	0.2x (100nM)						Wang and Fondell (2001)
HeLa hAR(S)+M-Luc(T)	DHT	Flutamide	13311-84-7	neg.	0.2x (100nM)						Wang and Fondell (2001)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	Flutamide	13311-84-7	neg.			pos.				Maness et al. (1998)
PALM hAR(S)+Luc(S)	DHT	Flutamide	13311-84-7				pos.				Schrader and Cooke (2000)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Flutamide	13311-84-7	neg.							Gaido et al. (1997)

Information Sorted by Substance Name and Assay

Assay Type*	Reference Androgen**	Substance Name	CASRN†	AGONISM Qualitative††	AGONISM Maximum Fold x (conc. µM)††	AGONISM EC50 (µM)††	ANTAG. ^{a,b} Qualitative††	ANTAG. ^{a,b} IC50 (µM)††	Prolif. Response ^a ††	RPP ^{a,b,††}	Reference
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Flutamide	13311-84-7				pos.	220			O'Connor et al. (1999)
Yeast(<i>S. cer</i>) hAR(S)+ gal(S)	DHT	Flutamide	13311-84-7	neg.			pos.				Moffat et al. (2001)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Flutamide	13311-84-7	neg.			pos.	22			O'Connor et al. (1998)
CHO hAR (S)+Luc (S)	DHT	Gestodene	60282-87-3	pos.							Deckers et al. (2000)
Yeast(<i>S. cer</i>) hAR(S)+ gal(S)	DHT	HEPES	7365-45-9	neg.			neg.				Moffat et al. (2001)
CHO hAR(T)+Luc(T)	R1881	2,2',3,4,4',5,5'-Heptachlorobiphenyl	35065-29-3	neg.			neg.				Bonefeld-Jorgenson et al. (2001)
CHO hAR(T)+Luc(T)	R1881	2,2',3,4,4',5'-Hexachlorobiphenyl	35065-28-2	neg.			pos.	1			Bonefeld-Jorgenson et al. (2001)
CHO hAR(T)+Luc(T)	R1881	2,2',4,4',5,5'-Hexachlorobiphenyl	35065-27-2	neg.			neg.				Bonefeld-Jorgenson et al. (2001)
PALM hAR(S)+Luc(S)	DHT	-Hexachlorocyclohexane	319-84-6	neg.			pos.	8.2			Schrader and Cooke (2000)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	-Hexachlorocyclohexane	319-85-7	neg.							Otsuka Pharmaceutical Co. (2001)
PALM hAR(S)+Luc(S)	DHT	-Hexachlorocyclohexane	319-85-7	neg.			neg.				Schrader and Cooke (2000)
PALM hAR(S)+Luc(S)	DHT	-Hexachlorocyclohexane	319-86-8	neg.			pos.	17.9			Schrader and Cooke (2000)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Hydramethylnone	67485-29-4	neg.			neg.				Otsuka Pharmaceutical Co. (2001)
CHO hAR(T)+Luc(T)	R1881	Hydroxyflutamide	52806-53-8				pos.	0.01			Vinggaard et al. (1999)
CV-1 hAR(T)+CAT(T)	R1881	Hydroxyflutamide	52806-53-8	neg.			pos.				Kemppainen et al. (1992)
CV-1 hAR(T)+Luc(T)	DHT	Hydroxyflutamide	52806-53-8				pos.				Kelce et al. (1995)
CV-1 hAR(T)+Luc(T)	DHT	Hydroxyflutamide	52806-53-8	pos.			pos.				Kemppainen and Wilson (1996)
CV-1 hAR(T)+Luc(T)	DHT	Hydroxyflutamide	52806-53-8	weak	10x (10µM)		pos.	0.1			Kemppainen et al. (1999)
CV-1 hAR(T)+Luc(T)*	DHT	Hydroxyflutamide	52806-53-8	pos.	2.1x (10µM)		pos.				Hartig et al. (2002)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	Hydroxyflutamide	52806-53-8	pos.			pos.				Maness et al. (1998)
MDA-MB-453-kb2 hAR(E)+Luc(S)	DHT	Hydroxyflutamide	52806-53-8				pos.	10			Wilson et al. (2002)
PALM hAR(S)+Luc(S)	R1881	Hydroxyflutamide	52806-53-8				pos.	0.1			Terouanne et al. (2000)

Information Sorted by Substance Name and Assay

Assay Type*	Reference Androgen**	Substance Name	CASRN†	AGONISM Qualitative††	AGONISM Maximum Fold x (conc. μM)††	AGONISM EC50 (μM)††	ANTAG. ^{a,b} Qualitative††	ANTAG. ^{a,b} IC50 (μM)††	Prolif. Response ^a ††	RPP ^{a,b,†} ††	Reference
PALM hAR(S)+Luc(S)	R1881	Hydroxyflutamide	52806-53-8	weak	5x (1μM)		pos.	10			Terouanne et al. (2000)
PC-3 hAR(T)+Luc(T)	R1881	Hydroxyflutamide	52806-53-8				pos.	0.02			Terouanne et al. (2000)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Hydroxyflutamide	52806-53-8	pos.		8.21					Gaido et al. (1997)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Hydroxyflutamide	52806-53-8	pos.		82	pos.				O'Connor et al. (1998)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	4-Hydroxytamoxifen	68047-06-3	neg.							Otsuka Pharmaceutical Co. (2001)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	ICI 182,780	129453-61-8	neg.			neg.				O'Connor et al. (1998)
PALM hAR(S)+Luc(S)	R1881	Inocoteron	83646-86-0	pos.	18x (1μM)		pos.	30			Terouanne et al. (2000)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Kepone	143-50-0	neg.							Otsuka Pharmaceutical Co. (2001)
CV-1 hAR(T)+Luc(T)	DHT	Kepone	143-50-0				neg.				Kelce et al. (1995)
PALM hAR(S)+Luc(S)	DHT	Kepone	143-50-0	neg.			pos.	6.9			Schrader and Cooke (2000)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Ketoconazole	65277-42-1	weak			neg.				O'Connor et al. (1998)
CHO hAR (S)+Luc (S)	DHT	11-Keto-15-dehydronorethisterone		pos.							Deckers et al. (2000)
CHO hAR (S)+Luc (S)	DHT	11-Ketonorethisterone	5210-27-5	pos.							Deckers et al. (2000)
CHO-K1 hAR(S)+Luc(S)	DHT	11-Ketotestosterone	564-35-2	pos.		0.0058					Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	11-Ketotestosterone	564-35-2	pos.		0.00151					Otsuka Pharmaceutical Co. (2001)
EPC rtAR () +CAT(T)	DHT	11-Ketotestosterone	564-35-2	pos.							Takeo and Yamashita (2000)
CHO hAR (S)+Luc (S)	DHT	Levonorgestrel	797-63-7	pos.							Deckers et al. (2000)
CHO-K1 hAR(S)+Luc(S)	DHT	Levonorgestrel	797-63-7	pos.		0.0016					Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Levonorgestrel	797-63-7	pos.		0.000373					Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Lindane	58-89-9	neg.							Otsuka Pharmaceutical Co. (2001)
PALM hAR(S)+Luc(S)	DHT	Lindane	58-89-9	neg.			neg.				Schrader and Cooke (2000)
PALM hAR(S)+Luc(S)	R1881	Lindane	58-89-9				neg.				Sultan et al. (2001)

Information Sorted by Substance Name and Assay

Assay Type*	Reference Androgen**	Substance Name	CASRN†	AGONISM ^b Qualitative††	AGONISM Maximum Fold x (conc. μM)††	AGONISM EC50 (μM)††	ANTAG. ^{a,b} Qualitative††	ANTAG. ^{a,b} IC50 (μM)††	Prolif. Response ^a ††	RPP ^{a,b,†} †	Reference
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Linuron	330-55-2	pos.							Otsuka Pharmaceutical Co. (2001)
CV-1 hAR(T)+Luc(T)	DHT	Linuron	330-55-2				pos.	10			Lambright et al. (2000)
MDA-MB-453-kb2 hAR(E)+Luc(S)	DHT	Linuron	330-55-2				pos.	5			Lambright et al. (2000)
MDA-MB-453-kb2 hAR(E)+Luc(S)	DHT	Linuron	330-55-2				pos.	5			Wilson et al. (2002)
CV-1 hAR(T)+Luc(T)	DHT	Medroxyprogesterone acetate	71-58-9	pos.	10x (0.1nM)		neg.				Kemppainen et al. (1999)
CV-1 hAR(T)+Luc(T)*	DHT	Medroxyprogesterone acetate	71-58-9	pos.	10x (0.01 μM)						Hartig et al. (2002)
MDA-MB-453 hAR(E)+Luc(T)*	DHT	Medroxyprogesterone acetate	71-58-9	pos.	64x (0.01 μM)						Hartig et al. (2002)
MDA-MB-453-kb2 hAR(E)+Luc(S)	DHT	Medroxyprogesterone acetate	71-58-9	pos.							Wilson et al. (2002)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Methoxychlor	72-43-5	neg.							Otsuka Pharmaceutical Co. (2001)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	Methoxychlor	72-43-5				pos.				Gaido et al. (2000)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	Methoxychlor	72-43-5				weak				Maness et al. (1998)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Methoxychlor	72-43-5	neg.							Gaido et al. (1997)
CHO-K1 hAR(S)+Luc(S)	DHT	Methyltestosterone	58-18-4	pos.		0.000135					Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Methyltestosterone	58-18-4	pos.		0.0000274					Otsuka Pharmaceutical Co. (2001)
EPC rAR () +CAT(T)	DHT	Methyltestosterone	58-18-4	pos.							Takeo and Yamashita (2000)
CHO hAR(T)+Luc(T)	R1881	Methyltrienolone	965-93-5	pos.				0.0001			Bonefeld-Jorgenson et al. (2001)
CHO hAR(T)+Luc(T)	R1881	Methyltrienolone	965-93-5	pos.							Vinggaard et al. (1999)
CHO hAR(T)+Luc(T)	R1881	Methyltrienolone	965-93-5	pos.							Vinggaard et al. (2000)
CV-1 hAR(T)+CAT(T)	R1881	Methyltrienolone	965-93-5	pos.	7.5x (0.01nM)						Kemppainen et al. (1992)
CV-1 hAR(T)+Luc(T)	DHT	Methyltrienolone	965-93-5	pos.	10x (0.001nM)		neg.				Kemppainen et al. (1999)
LNCaP-FGC hAR(E)+CP	DHT	Methyltrienolone	965-93-5						pos.	10,000	Sonnenschein et al. (1989)
PALM hAR(S)+Luc(S)	R1881	Methyltrienolone	965-93-5	pos.							Sultan et al. (2001)

Information Sorted by Substance Name and Assay

Assay Type*	Reference Androgen**	Substance Name	CASRN†	AGONISM ^b Qualitative††	AGONISM Maximum Fold x (conc. µM)††	AGONISM EC50 (µM)††	ANTAG. ^{a,b} Qualitative††	ANTAG. ^{a,b} IC50 (µM)††	Prolif. Response ^a ††	RPP ^{a,b,††}	Reference
PALM hAR(S)+Luc(S)	R 1881	Methyltrienolone	965-93-5	pos.							Terouanne et al. (2000)
PC-3 hAR(T)+Luc(T)	R 1881	Methyltrienolone	965-93-5	pos.							Terouanne et al. (2000)
CV-1 hAR(T)+Luc(T)	DHT	Mibolerone	3704-09-4	pos.	10x (0.001nM)		neg.				Kemppainen et al. (1999)
LNCaP-FGC hAR(E)+CP	DHT	Mibolerone	3704-09-4						pos.	10,000	Sonnenschein et al. (1989)
PALM hAR(S)+Luc(S)	R 1881	Mibolerone	3704-09-4	pos.		0.00003					Terouanne et al. (2000)
CHO-K1 hAR(S)+Luc(S)	DHT	Mifepristone	84371-65-3	pos.		0.0136					Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Mifepristone	84371-65-3	neg.							Otsuka Pharmaceutical Co. (2001)
PALM hAR(S)+Luc(S)	R 1881	Mifepristone	84371-65-3	pos.	4x (1µM)		pos.	0.05			Terouanne et al. (2000)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Mifepristone	84371-65-3	pos.		2100					O'Connor et al. (2000)
CV-1 hAR(T)+CAT(T)	R 1881	Mifepristone	84371-65-3	pos.	10x (10nM)		pos.				Kemppainen et al. (1992)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Mirex	2385-85-5	neg.							Otsuka Pharmaceutical Co. (2001)
PALM hAR(S)+Luc(S)	DHT	Mirex	2385-85-5	neg.			neg.				Schrader and Cooke (2000)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	Monohydroxy-DDE					pos.				Gaido et al. (2000)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	Monohydroxymethoxychlor	28463-03-8				pos.				Gaido et al. (2000)
LNCaP-FGC hAR(E)+CP	DHT	Moxestrol	34816-55-2						neg.		Sonnenschein et al. (1989)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Nafoxidine	1847-63-8	neg.							Otsuka Pharmaceutical Co. (2001)
MDA-MB-453-kb2 hAR(E)+Luc(S)	DHT	Neburon	555-37-3				pos.	10			Wilson et al. (2002)
PALM hAR(S)+Luc(S)	R 1881	Nilutamide	63612-50-0				pos.	0.3			Terouanne et al. (2000)
PALM hAR(S)+Luc(S)	R 1881	Nilutamide	63612-50-0	weak	5x (1µM)		pos.	10			Terouanne et al. (2000)
PC-3 hAR(T)+Luc(T)	R 1881	Nilutamide	63612-50-0				pos.	0.15			Terouanne et al. (2000)
PALM hAR(S)+Luc(S)	DHT	<i>cis</i> -Nonachlor	5103-73-1	neg.			neg.				Schrader and Cooke (2000)
PALM hAR(S)+Luc(S)	DHT	<i>trans</i> -Nonachlor	39765-80-5	neg.			neg.				Schrader and Cooke (2000)

Information Sorted by Substance Name and Assay

Assay Type*	Reference Androgen**	Substance Name	CASRN†	AGONISM Qualitative††	AGONISM Maximum Fold x (conc. µM)††	AGONISM EC50 (µM)††	ANTAG. ^{a,b} Qualitative††	ANTAG. ^{a,b} IC50 (µM)††	Prolif. Response ^a ††	RPP ^{a,b,††}	Reference
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	<i>p</i> - Nonylphenol	104-40-5	neg.							Otsuka Pharmaceutical Co. (2001)
Yeast(<i>S. cer</i>) hAR(S)+ gal(S)	DHT	<i>p</i> -Nonylphenol	104-40-5	neg.							Gaido et al. (1997)
Yeast(<i>S. cer</i>) hAR(S)+ gal(S)	DHT	<i>p</i> -Nonylphenol	104-40-5	pos.		2	neg.	0.001			Moffat et al. (2001)
Yeast(<i>S. cer</i>) hAR(S)+ gal(S)	DHT	1-O-(Nonylphenyl)-a,b-D-glucopyranosiduric acid		neg.			neg.				Moffat et al. (2001)
CHO hAR (S)+Luc (S)	DHT	Norethisterone	68-22-4	pos.							Deckers et al. (2000)
CHO-K1 hAR(S)+Luc(S)	DHT	Norethisterone	68-22-4	pos.		0.00716					Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Norethisterone	68-22-4	pos.		0.00371					Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(S)+Luc(S)	DHT	Norgestrel	6533-00-2	pos.		0.00102					Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Norgestrel	6533-00-2	pos.		0.000404					Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(S)+Luc(S)	DHT	19-Nortestosterone	434-22-0	pos.		0.00022					Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	19-Nortestosterone	434-22-0	pos.		0.0000923					Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	<i>p</i> - <i>tert</i> -Octylphenol	140-66-9	neg.							Otsuka Pharmaceutical Co. (2001)
Yeast(<i>S. cer</i>) hAR(S)+ gal(S)	DHT	<i>p</i> - <i>tert</i> -Octylphenol	140-66-9	neg.			neg.				Moffat et al. (2001)
Yeast(<i>S. cer</i>) hAR(S)+ gal(S)	DHT	1-O-(Octylphenyl)-a,b-D-glucopyranosiduronic acid		neg.			neg.				Moffat et al. (2001)
CV-1 hAR(T)+Luc(T)	DHT	Oxandrolone	53-39-4	pos.	10x (0.001µM)		neg.				Kemppainen et al. (1999)
PALM hAR(S)+Luc(S)	DHT	Oxychlordane	27304-13-8	neg.			neg.				Schrader and Cooke (2000)
Yeast(<i>S. cer</i>) hAR(S)+ gal(S)	DHT	Permethrin	52645-53-1	neg.							Gaido et al. (1997)
CHO hAR(T)+Luc(T)	R1881	Phenanthrene	85-01-8				neg.				Vinggaard et al. (2000)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Phenobarbital, sodium salt	57-30-7	neg.							Otsuka Pharmaceutical Co. (2001)
Yeast(<i>S. cer</i>) hAR(S)+ gal(S)	DHT	Phenothrin	26002-80-2	neg.							Gaido et al. (1997)
PALM hAR(S)+Luc(S)	DHT	Photomirex	39801-14-4	neg.			neg.				Schrader and Cooke (2000)
LNCaP-FGC hAR(E)+CP	DHT	Pregnenolone	145-13-1						pos.	1	Sonnenschein et al. (1989)

Information Sorted by Substance Name and Assay

Assay Type*	Reference Androgen**	Substance Name	CASRN†	AGONISM Qualitative††	AGONISM Maximum Fold x (conc. μ M)††	AGONISM EC50 (μ M)††	ANTAG. Qualitative††	ANTAG. IC50 (μ M)††	Prolif. Response ††	RPP ^{a,b} ††	Reference
CHO hAR(T)+Luc(T)	R1881	Procymidone	32809-16-8				pos.	5			Vinggaard et al. (1999)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Procymidone	32809-16-8	neg.							Otsuka Pharmaceutical Co. (2001)
MDA-MB-453-kb2 hAR(E)+Luc(S)	DHT	Procymidone	32809-16-8				pos.	10			Wilson et al. (2002)
CHO hAR(T)+CAT(T)+ gal(T)	DHT	Progesterone	57-83-0	neg.							Deslypere et al. (1992)
CHO hAR(T)+Luc(T)	R1881	Progesterone	57-83-0	pos.			pos.	0.1			Vinggaard et al. (1999)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Progesterone	57-83-0	neg.							Otsuka Pharmaceutical Co. (2001)
CV-1 hAR(T)+CAT(T)	R1881	Progesterone	57-83-0	pos.	7.0x (100nM)						Kempainen et al. (1992)
CV-1 hAR(T)+Luc(T)	DHT	Progesterone	57-83-0	pos.							Kempainen and Wilson (1996)
CV-1 hAR(T)+Luc(T)	DHT	Progesterone	57-83-0	pos.	10x (0.1 μ M)		weak	0.5			Kempainen et al. (1999)
EPC α AR () +CAT(T)	DHT	Progesterone	57-83-0	neg.							Takeo and Yamashita (2000)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	Progesterone	57-83-0	pos.			weak				Maness et al. (1998)
LNCaP-FGC hAR(E)+CP	DHT	Progesterone	57-83-0						pos.	100	Sonnenschein et al. (1989)
PALM hAR(S)+Luc(S)	DHT	Progesterone	57-83-0	pos.							Schrader and Cooke (2000)
PALM hAR(S)+Luc(S)	R1881	Progesterone	57-83-0	weak	10x (1 μ M)						Terouanne et al. (2000)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Progesterone	57-83-0	pos.		0.0089					Gaido et al. (1997)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Progesterone	57-83-0	pos.		5.2					O'Connor et al. (2000)
LNCaP-FGC hAR(E)+CP	DHT	Promegestone	34184-77-5						pos.	1	Sonnenschein et al. (1989)
PALM hAR(S)+Luc(S)	R1881	Promegestone	34184-77-5	weak	40x (1 μ M)		pos.	0.09			Terouanne et al. (2000)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Propylthiourea	927-67-3	neg.							Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Prothiofos	34643-46-4	pos.			weak				Otsuka Pharmaceutical Co. (2001)
CHO hAR(T)+Luc(T)	R1881	Pyrene	129-00-0				neg.				Vinggaard et al. (2000)
PALM hAR(S)+Luc(S)	R1881	R2956	42438-88-0	pos.	45x (1 μ M)		pos.	45			Terouanne et al. (2000)

Information Sorted by Substance Name and Assay

Assay Type*	Reference Androgen**	Substance Name	CASRN†	AGONISM Qualitative††	AGONISM Maximum Fold x (conc. µM)††	AGONISM EC50 (µM)††	ANTAG. ^{a,b} Qualitative††	ANTAG. ^{a,b} IC50 (µM)††	Prolif. Response ^a ††	RPP ^{a,b,††}	Reference
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Rimsulfuron	122931-48-0	neg.							Otsuka Pharmaceutical Co. (2001)
CV-1 hAR(T)+Luc(T)	DHT	RU56187	143782-25-6	pos.	10x (0.01µM)		weak	0.1nM			Kemppainen et al. (1999)
CV-1 mAR(T)+CAT(T)	DHT	RU 59063	155180-53-3	pos.							Van Dort et al. (2000)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	-Sitosterol	83-46-5	neg.							Otsuka Pharmaceutical Co. (2001)
CHO hAR(T)+Luc(T)	R1881	Spironolactone	52-01-7				pos.	0.5			Vinggaard et al. (1999)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Spironolactone	52-01-7	pos.			neg.				Otsuka Pharmaceutical Co. (2001)
PALM hAR(S)+Luc(S)	R1881	Spironolactone	52-01-7	pos.	40x (1µM)		pos.	0.09			Terouanne et al. (2000)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Tamoxifen	10540-29-1	neg.							Otsuka Pharmaceutical Co. (2001)
CHO hAR(T)+CAT(T)+ gal(T)	DHT	Testosterone	58-22-0	pos.	100x (1nM)						Deslypere et al. (1992)
CHO-K1 hAR(S)+Luc(S)	DHT	Testosterone	58-22-0	pos.		0.000527					Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Testosterone	58-22-0	pos.		0.000107					Otsuka Pharmaceutical Co. (2001)
CV-1 hAR(T)+CAT(T)	R1881	Testosterone	58-22-0	pos.	7.5x (0.01nM)						Kemppainen et al. (1992)
CV-1 hAR(T)+Luc(T)	DHT	Testosterone	58-22-0	pos.	10x (0.01nM)		neg.				Kemppainen et al. (1999)
EPC rtAR () +CAT(T)	DHT	Testosterone	58-22-0	pos.							Takeo and Yamashita (2000)
HeLa hAR(S)+DS-Luc(T)	DHT	Testosterone	58-22-0	pos.	6x (100nM)						Wang and Fondell (2001)
HeLa hAR(S)+M-Luc(T)	DHT	Testosterone	58-22-0	pos.	5x (100nM)						Wang and Fondell (2001)
HeLa hAR(S)+PB-Luc(T)	DHT	Testosterone	58-22-0	pos.	6x (100nM)						Wang and Fondell (2001)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	Testosterone	58-22-0	pos.							Maness et al. (1998)
LNCaP-FGC hAR(E)+CP	DHT	Testosterone	58-22-0						pos.	100	Sonnenschein et al. (1989)
PALM hAR(S)+Luc(S)	R1881	Testosterone	58-22-0	pos.							Sultan et al. (2001)
PALM hAR(S)+Luc(S)	R1881	Testosterone	58-22-0	pos.		0.0002					Terouanne et al. (2000)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Testosterone	58-22-0	pos.		0.0047					Gaido et al. (1997)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Testosterone	58-22-0	pos.		0.0099					O'Connor et al. (1999)
Yeast(<i>S. cer</i> YPH500) hAR(S)+ gal(S)	DHT	Testosterone	58-22-0	pos.		0.012					O'Connor et al. (2000)

Information Sorted by Substance Name and Assay

Assay Type*	Reference Androgen**	Substance Name	CASRN†	AGONISM Qualitative††	AGONISM Maximum Fold x (conc. µM)††	AGONISM EC50 (µM)††	ANTAG. ^{a,b} Qualitative††	ANTAG. ^{a,b} IC50 (µM)††	Prolif. Response ^a ††	RPP ^{a,b,†,†}	Reference
PALM hAR(S)+Luc(S)	DHT	2,3,7,8-Tetrachlorodibenzo-p-dioxin	1746-01-6	neg.			pos.	6.5			Schrader and Cooke (2000)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Toxaphene	8001-35-2	neg.							Otsuka Pharmaceutical Co. (2001)
PALM hAR(S)+Luc(S)	DHT	Toxaphene	8001-35-2	pos.		10	weak	1935			Schrader and Cooke (2000)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Tralomethrin	66841-25-6	pos.			neg.				Otsuka Pharmaceutical Co. (2001)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	Trihydroxymethoxychlor					neg.				Gaido et al. (2000)
HepG2 hAR(T)+Luc(T)+ gal(T)	DHT	Trimethoxymethoxychlor					neg.				Gaido et al. (2000)
CHO hAR(T)+Luc(T)	R1881	Vinclozolin	50471-44-8				pos.	0.5			Vinggaard et al. (1999)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Vinclozolin	50471-44-8	neg.			weak				Otsuka Pharmaceutical Co. (2001)
MDA-MB-453-kb2 hAR(E)+Luc(S)	DHT	Vinclozolin	50471-44-8				pos.	0.05			Wilson et al. (2002)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Zearalenone	17924-92-4	neg.							Otsuka Pharmaceutical Co. (2001)
CHO-K1 hAR(T)+Luc(T)+EGFP(T)	DHT	Zearanol	26538-44-3	neg.							Otsuka Pharmaceutical Co. (2001)

* Assays used for testing listed alphabetically.

**R1881 = Methyltrienolone, DHT = 5 - Dihydrotestosterone, T=Testosterone, M=Mibolerone.

† Empty cells indicate that no CASRN could be found.

†† Empty cells indicate that no information was provided in the publication.

^aANTAG. = Antagonism; Prolif. Resp. = proliferative response; RPP = relative proliferative potency.

^b Neg. and pos. indicate that a negative or positive response was reported for a specific substance in a specific assay.

hAR(E) indicates that the hAR is endogenous.

hAR(T) indicates that the hAR has been transiently transfected into the cell line.

hAR(S) indicates that the hAR has been stabilized in the cell by selection of a transiently transfected cell line.

Luc/CAT(T) indicates that the reporter gene was transiently transfected into the cell line.

Luc/CAT(S) indicates that the reporter gene has been stabilized in the cell by selection of a transiently transfected cell line.

CHO hAR(T)+CAT(T)+ gal(T) are Chinese hamster ovary cells transiently transfected with the human AR and the MMTV response element linked to the chloramphenicol acetyltransferase gene plus a plasmid harboring the -galactosidase gene.

CHO hAR(T)+Luc(T) are Chinese hamster ovary cells transiently transfected with the human AR and the MMTV response element linked to the luciferase gene.

CHO-K1 hAR(S)+Luc(S) are Chinese hamster ovary cells stably transfected with both the human AR and the IND response element linked to the luciferase gene.

CHO-K1-hAR(T)+IND-ARE-luc+EGFP are Chinese hamster ovary cells transiently transfected with the human AR and the IND response element linked to the luciferase gene plus a plasmid harboring the green fluorescent protein gene to measure toxicity.

CV1 hAR(T)+CAT(T) are CV1 cells transiently transfected with the human AR and the MMTV response element linked to the chloramphenicol acetyltransferase gene.

CV1 hAR(T)+Luc(T) are CV1 cells transiently transfected with the human AR and the MMTV response element linked to the luciferase gene.

CV1 hAR(T)+Luc(T)* are CV1 cells that are transduced with a virion carrying the genes for the human AR and the MMTV response element linked to the luciferase gene.

CV-1 mAR(T)+CAT(T) are CV1 cells transiently transfected with the mouse AR and the chloramphenicol acetyltransferase gene.

EPC rAR (T)+CAT(T) are fish cells transiently transfected with the rainbow trout AR and the tyrosine kinase response element linked to the chloramphenicol acetyltransferase gene.

HeLa hAR(S)+Luc(T) are HeLa cells with stable human AR gene and a reporter plasmid linked to three different response elements linked to the luciferase gene (M, DS and PB-Luc).

HepG2 hAR(T)+Luc(T)+ gal(T) are Hep G2 cells transiently transfected with the human AR and the MMTV response element linked to the luciferase gene plus a plasmid harboring the -galactosidase gene.

LNCaP-FGC hAR(E)+CP cells are cells from human supraclavicular lymph node from patient with prostatic adenocarcinoma used to measure cell proliferation.

MDA-MB-453 hAR(E)+Luc(T)* are MDA-MB-453 cells with an endogenous human AR gene and a transduced virion containing the luciferase reporter gene.

MDA-MB-453-kb2 hAR(E)+Luc(S) are MDA cells with an endogenous human AR gene and the stably transfected MMTV response element linked to the luciferase gene.

PALM hAR(S)+Luc(S) are PC-3 cells stably transfected with both the human AR and the MMTV response element linked to the luciferase gene.

PC-3 hAR(T)+Luc(T) are PC-3 cells transiently with the human AR and the MMTV response element linked to the luciferase gene.

Yeast (*S. cerevisiae*) hAR(S)+ gal(S) are *Saccharomyces cerevisiae* cells stably transfected with both the human AR and the metallotheinin response element linked to the -galactosidase gene.

Yeast (*S. cerevisiae* YPH500) hAR(S)+ gal(S) are *Saccharomyces cerevisiae* YPH500 cells stably transfected with both the human AR and the metallotheinin response element linked to the -galactosidase gene.

Values in italics have been estimated from a graphical representation of the data.